RBA Wealth Management LLC Sells 277 Shares of Johnson & Johnson (NYSE:JNJ)

RBA Wealth Management LLC reduced its stake in Johnson & Johnson (NYSE:JNJ) by 15.4% during the third quarter, Holdings Channel.com reports. The firm owned 1,525 shares of the company’s stock after selling 277 shares during the quarter. RBA Wealth Management LLC’s holdings in Johnson & Johnson were worth $247,000 as of its most recent filing with the SEC.

A number of other institutional investors also recently bought and sold shares of JNJ. CGN Advisors LLC raised its holdings in Johnson & Johnson by 3.1% during the first quarter. CGN Advisors LLC now owns 22,083 shares of the company’s stock valued at $3,493,000 after acquiring an additional 664 shares during the period. Strategic Planning Group LLC raised its holdings in Johnson & Johnson by 24.1% during the first quarter. Strategic Planning Group LLC now owns 12,289 shares of the company’s stock valued at $1,944,000 after acquiring an additional 2,390 shares during the period. Austin Private Wealth LLC raised its holdings in Johnson & Johnson by 5.1% during the first quarter. Austin Private Wealth LLC now owns 9,266 shares of the company’s stock valued at $1,429,000 after acquiring an additional 453 shares during the period. Crane Advisory LLC increased its holdings in shares of Johnson & Johnson by 38.0% in the first quarter. Crane Advisory LLC now owns 10,707 shares of the company’s stock worth $1,633,000 after purchasing an additional 2,951 shares during the last quarter. Finally, McNaughton Wealth Management LLC increased its holdings in shares of Johnson & Johnson by 6.9% in the first quarter. McNaughton Wealth Management LLC now owns 5,580 shares of the company’s stock worth $883,000 after purchasing an additional 361 shares during the last quarter. 69.55% of the stock is owned by institutional investors.

Johnson & Johnson Stock Up 0.4 %

Shares of NYSE:JNJ opened at $163.45 on Wednesday. Johnson & Johnson has a 1 year low of $143.13 and a 1 year high of $168.85. The business has a 50 day simple moving average of $163.14 and a two-hundred day simple moving average of $154.84. The firm has a market capitalization of $393.37 billion, a PE ratio of 10.19, a price-to-earnings-growth ratio of 2.65 and a beta of 0.52. The company has a debt-to-equity ratio of 0.44, a current ratio of 1.07 and a quick ratio of 0.85.

Johnson & Johnson (NYSE:JNJ) last announced its earnings results on Tuesday, October 15th. The company reported $2.42 earnings per share (EPS) for the quarter, beating the consensus estimate of $2.21 by $0.21. Johnson & Johnson had a return on equity of 36.60% and a net margin of 46.34%. The business had revenue of $22.47 billion during the quarter, compared to analyst estimates of $22.17 billion. During the same quarter in the previous year, the business earned $2.66 earnings per share. The company’s revenue for the quarter was up 5.2% compared to the same quarter last year. On average, equities analysts predict that Johnson & Johnson will post 10 EPS for the current year.

Johnson & Johnson Announces Dividend

The business also recently declared a quarterly dividend, which will be paid on Tuesday, December 10th. Stockholders of record on Tuesday, November 26th will be paid a dividend of $1.24 per share. This represents a $4.96 annualized dividend and a dividend yield of 3.03%. The ex-dividend date of this dividend is Tuesday, November 26th. Johnson & Johnson’s dividend payout ratio is presently 30.92%.

Insider Activity

In other news, VP Robert J. Decker sold 5,635 shares of Johnson & Johnson stock in a transaction that occurred on Friday, August 30th. The shares were sold at an average price of $165.06, for a total transaction of $930,113.10. Following the completion of the sale, the vice president now owns 18,973 shares of the company’s stock, valued at approximately $3,131,683.38. The trade was a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. Insiders own 0.16% of the company’s stock.

Analyst Ratings Changes

Several equities research analysts have recently issued reports on JNJ shares. Daiwa Capital Markets cut Johnson & Johnson from an “outperform” rating to a “neutral” rating and reduced their target price for the stock from $160.00 to $150.00 in a report on Tuesday, July 23rd. Royal Bank of Canada lifted their target price on Johnson & Johnson from $178.00 to $181.00 and gave the stock an “outperform” rating in a report on Wednesday, October 16th. Citigroup lifted their target price on Johnson & Johnson from $180.00 to $185.00 and gave the stock a “buy” rating in a report on Wednesday, October 16th. Cantor Fitzgerald reaffirmed an “overweight” rating and issued a $215.00 target price on shares of Johnson & Johnson in a report on Wednesday, October 16th. Finally, The Goldman Sachs Group reduced their target price on Johnson & Johnson from $160.00 to $155.00 and set a “neutral” rating on the stock in a report on Friday, July 19th. Six investment analysts have rated the stock with a hold rating, seven have assigned a buy rating and one has issued a strong buy rating to the company. According to data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and a consensus target price of $175.93.

About Johnson & Johnson

Johnson & Johnson, together with its subsidiaries, researches, develops, manufactures, and sells various products in the healthcare field worldwide. The company's Innovative Medicine segment offers products for various therapeutic areas, such as immunology, including rheumatoid arthritis, psoriatic arthritis, inflammatory bowel disease, and psoriasis; infectious diseases comprising HIV/AIDS; neuroscience, consisting of mood disorders, neurodegenerative disorders, and schizophrenia; oncology, such as prostate cancer, hematologic malignancies, lung cancer, and bladder cancer; cardiovascular and metabolism, including thrombosis, diabetes, and macular degeneration; and pulmonary hypertension comprising pulmonary arterial hypertension through retailers, wholesalers, distributors, hospitals, and healthcare professionals for prescription use.